Literature DB >> 28626516

Inhibitors of Adaptor-Associated Kinase 1 (AAK1) May Treat Neuropathic Pain, Schizophrenia, Parkinson's Disease, and Other Disorders.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2017        PMID： 28626516      PMCID： PMC5467186          DOI： 10.1021/acsmedchemlett.7b00208

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  The Ark1/Prk1 family of protein kinases. Regulators of endocytosis and the actin skeleton.

Authors:  Elizabeth Smythe; Kathryn R Ayscough
Journal:  EMBO Rep       Date:  2003-03       Impact factor: 8.807

2.  AAK1 identified as an inhibitor of neuregulin-1/ErbB4-dependent neurotrophic factor signaling using integrative chemical genomics and proteomics.

Authors:  Letian Kuai; Shao-En Ong; Jon M Madison; Xiang Wang; Jeremy R Duvall; Timothy A Lewis; Catherine J Luce; Sean D Conner; David A Pearlman; John L Wood; Stuart L Schreiber; Steven A Carr; Edward M Scolnick; Stephen J Haggarty
Journal:  Chem Biol       Date:  2011-07-29

3.  Inhibition of clathrin-mediated endocytosis prevents amyloid β-induced axonal damage.

Authors:  Tomoharu Kuboyama; Young-A Lee; Hiroaki Nishiko; Chihiro Tohda
Journal:  Neurobiol Aging       Date:  2015-02-13       Impact factor: 4.673

4.  Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain.

Authors:  Walter Kostich; Brian D Hamman; Yu-Wen Li; Sreenivasulu Naidu; Kumaran Dandapani; Jianlin Feng; Amy Easton; Clotilde Bourin; Kevin Baker; Jason Allen; Katerina Savelieva; Justin V Louis; Manoj Dokania; Saravanan Elavazhagan; Pradeep Vattikundala; Vivek Sharma; Manish Lal Das; Ganesh Shankar; Anoop Kumar; Vinay K Holenarsipur; Michael Gulianello; Ted Molski; Jeffrey M Brown; Martin Lewis; Yanling Huang; Yifeng Lu; Rick Pieschl; Kevin O'Malley; Jonathan Lippy; Amr Nouraldeen; Thomas H Lanthorn; Guilan Ye; Alan Wilson; Anand Balakrishnan; Rex Denton; James E Grace; Kimberley A Lentz; Kenneth S Santone; Yingzhi Bi; Alan Main; Jon Swaffield; Ken Carson; Sandhya Mandlekar; Reeba K Vikramadithyan; Susheel J Nara; Carolyn Dzierba; Joanne Bronson; John E Macor; Robert Zaczek; Ryan Westphal; Laszlo Kiss; Linda Bristow; Charles M Conway; Brian Zambrowicz; Charles F Albright
Journal:  J Pharmacol Exp Ther       Date:  2016-07-13       Impact factor: 4.030
  4 in total
  3 in total

1.  Identification of miRNA and Their Regulatory Effects Induced by Total Flavonoids From Dracocephalum moldavica in the Treatment of Vascular Dementia.

Authors:  Mimin Liu; Guangzhi Shan; Hailun Jiang; Li Zeng; Kaiyue Zhao; Yiran Li; Ghulam Md Ashraf; Zhuorong Li; Rui Liu
Journal:  Front Pharmacol       Date:  2021-12-06       Impact factor: 5.810

2.  miRNA-384-3p alleviates sevoflurane-induced nerve injury by inhibiting Aak1 kinase in neonatal rats.

Authors:  Yuanyuan Chen; Xuan Gao; Hao Pei
Journal:  Brain Behav       Date:  2022-06-20       Impact factor: 3.405

3.  Dysregulation of the AP2M1 phosphorylation cycle by LRRK2 impairs endocytosis and leads to dopaminergic neurodegeneration.

Authors:  Qinfang Liu; Judith Bautista-Gomez; Daniel A Higgins; Jianzhong Yu; Yulan Xiong
Journal:  Sci Signal       Date:  2021-07-27       Impact factor: 8.192
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.